Status:
UNKNOWN
The Efficacy of Immunodetection Point Inhibitors for Advanced Esophageal Cancer
Lead Sponsor:
Sun Yat-sen University
Conditions:
Esophageal Cancer
Eligibility:
All Genders
18-80 years
Brief Summary
Esophageal cancer is one of the most common malignancies of the digestive system. Esophageal squamous cell carcinoma is the main type of esophageal cancer, accounting for more than 90% of esophageal c...
Detailed Description
Esophageal cancer is one of the most common malignant tumors of the digestive system. Esophageal squamous cell carcinoma, or esophageal squamous cell carcinoma for short, is the main type of esophagea...
Eligibility Criteria
Inclusion
- age above 18, male or female.
- patients with esophageal cancer confirmed by pathology through tumor biopsy or puncture tissue.
- the patient was assessed as untreatable by surgery.
- patients received second-line or third-line chemotherapy and were treated with immunodetector point inhibitors.
- the patient had complete preliminary pathological information, tumor site, pathological type and other information.
- the patient must have adequate tumor tissue or 5-10 FFPE white tablets to provide; After treatment, patients were returned to the hospital for re-examination every 3 treatment cycles, and plasma and peripheral blood samples could be obtained during the whole process.
- other indicators of the patients met the general clinical trial enrollment conditions.
- subjects read and fully understand the instructions to patients, and sign the informed consent.
Exclusion
- blood samples cannot be obtained before treatment.
- the patient has clear infection status.
- the patient has other serious diseases besides esophageal cancer.
- (5) current patients with alcoholism or drug abuse. (6) pregnant female patients. (7) the patient has a clear history of neurological or mental disorders.
Key Trial Info
Start Date :
May 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2021
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04074447
Start Date
May 1 2019
End Date
May 1 2021
Last Update
September 9 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060